Haemonetics Corporation
HAEHaemonetics Corporation (HAE) is a global healthcare company specializing in blood management solutions. Founded in 1971, it provides devices, software, and services for blood collection, processing, and analysis used in hospitals, blood banks, and plasma centers. The company focuses on improving outcomes in transfusion medicine and hemostasis through innovative technology and expertise.
Company News
The global therapeutic apheresis market is projected to grow from USD 3.84 billion in 2025 to USD 8.94 billion by 2035, at a CAGR of 7.9%. Growth is driven by increased prevalence of chronic and autoimmune diseases, technological advancements in automated systems, and improved reimbursement policies. Key players include Terumo BCT, Fresenius Kabi...
Haemonetics Corporation announced the acquisition of Ireland-based Vivasure Medical Limited for €100 million upfront plus up to €85 million in milestone-based payments. The deal adds Vivasure's PerQseal Elite system, a bioabsorbable patch for large-bore vascular access closure, to Haemonetics' interventional portfolio. The technology has rece...
The Patient Blood Management market is projected to grow from $13.9 billion in 2025 to $23 billion by 2033, driven by AI-enhanced analytics, autologous transfusion technologies, and advancements in blood conservation techniques.
Haemonetics reported Q1 FY2026 financial results with revenue of $321.4 million, missing analyst expectations. Despite revenue decline, the company showed strong organic growth in Plasma and Hospital segments and improved margins.
The global blood bank market is expected to grow significantly from 2025 to 2032, driven by the rising incidence of blood disorders, chronic illnesses, and accidents, as well as advancements in blood bank technologies and increased awareness about blood donation.
